How do the results and study design of LEADER differ from the CV outcomes study that evaluated lixisenatide in patients with T2D? Was the CV protection seen in LEADER observed in diabetic patients on statins? How does LEADER differ from the EMPA-REG study?

How do the results and study design of LEADER differ from the CV outcomes study that evaluated lixisenatide in patients with T2D? Was the CV protection seen in LEADER observed in diabetic patients on statins? How does LEADER differ from the EMPA-REG study?

How do the results and study design of LEADER differ from the CV outcomes study that evaluated lixisenatide in patients with T2D? Was the CV protection seen in LEADER observed in diabetic patients on statins? How does LEADER differ from the EMPA-REG study?


Created by

CMEducation Resources IQ&A Interactive Intelligence Zone

Presenter

Robert Henry, MD

Robert Henry, MD

Chief, Center for Metabolic Research
Chief, Section of Endocrinology, Metabolism & Diabetes
Veterans Affairs Healthcare System
Professor of Medicine‚ Department of Medicine
Division of Endocrinology and Metabolism
University of California‚ San Diego